Table II.
Antibiotic susceptibility patterns at different study centres against Escherichia coli and Klebsiella pneumoniae
| Centre | Organism | AMK (%) | CTX (%) | CAZ (%) | FEP (%) | TZP (%) | IMP (%) | MER (%) | CFP-SUL (%) | CST (%) | TET (%) | ERT (%) | CIP (%) | CFD (%) | CHL (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIIMS, New Delhi | E. coli | 90 (45/50) | 20 (10/50) | 22 (11/50) | 24 (12/50) | 64 (32/50) | 88 (44/50) | 56 (28/50) | 60 (30/50) | 100 (50/50) | 72 (36/50) | 46 (12/26) | 44 (22/50) | ND | 79 (19/24) |
| K. pneumoniae | 55 (28/51) | 12 (6/51) | 12 (6/51) | 12 (6/51) | 29 (15/51) | 57 (29/51) | 41 (21/51) | 33 (17/51) | 100 (51/51) | 55 (28/51) | ND | 33 (17/51) | ND | 49 (25/51) | |
| PGIMER, Chandigarh | E. coli | 78 (50/64) | 13 (8/64) | 9 (6/64) | 11 (7/64) | 44 (28/64) | 67 (43/64) | 56 (23/41) | 49 (20/14) | 100 (40/40) | 32 (11/34) | ND | 12 (5/41) | ND | 80 (33/41) |
| K. pneumoniae | 39 (26/67) | 15 (10/67) | 13 (9/67) | 15 (10/67) | 25 (17/67) | 49 (33/67) | 20 (8/40) | 23 (9/40) | 100 (38/38) | 76 (26/34) | ND | 20 (8/40) | 12 (3/25) | 78 (31/40) | |
| CMC, Vellore | E. coli | 82 (73/89) | 20 (18/89) | 22 (20/89) | 26 (23/89) | 56 50/89 | 71 (63/89) | 69 (61/89) | 60 (53/89) | 100 (89/89) | 36 (32/89) | ND | 24 (21/89) | 14 (6/42) | 72 (48/67) |
| K. pneumoniae | 62 (51/82) | 41 (34/82) | 40 (33/82) | 40 (33/82) | 44 36/82 | 55 (45/82) | 56 (46/82) | 48 (39/82) | 94 (77/82) | 73 (60/82) | 70 (23/33) | 49 (40/82) | 24 (8/33) | 58 (34/59) | |
| JIPMER, Puducherry | E. coli | 46 (58/125) | 47 (59/125) | 48 (60/125) | 62 (77/125) | 65 (81/125) | 66 (82/125) | 66 (82/125) | 64 (61/95) | 97 (92/95) | 57 (54/95) | 72 (39/54) | 43 (54/125) | 50 (15/30) | 89 (63/71) |
| K. pneumoniae | 71 (67/95) | 56 (53/95) | 51 (48/95) | 48 (46/95) | 54 (51/95) | 59 (56/95) | 61 (58/95) | 65 (41/63) | 100 (63/63) | 60 (38/63) | 50 (15/30) | 49 (47/95) | 52 (32/62) | 94 (59/63) |
Results presented in the form of per cent sensitivity (number of sensitive/total number of isolates). AMK, amikacin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin- tazobactam; IMP, imipenem; MER, meropenem; CFS-SUL, cefoperazone-sulbactam; TET, tetracycline; ERT, ertapene; CIP, ciprofloxacin; CFD, cefpodoxime; CHL, chloramphenicol; CST, colistin; ND, not done (tested); AIIMS, All India Institute of Medical Sciences; CMC, Christian Medical College; JIPMER, Jawaharlal Institute of Postgraduate Medical Education & Research; PGIMER, Postgraduate Institute of Medical Education & Research